Perbandingan Utilitas Biaya Amlodipine Dan Candesartan Pada Terapi Hipertensi Menggunakan Instrumen Eq-5d-5l

Hypertension is a major non-communicable disease with a high prevalence and requires long-term therapy, making the selection of cost-effective treatment essential. This study aimed to compare the cost utility of amlodipine and candesartan in the treatment of hypertension using the EQ-5D-5L instrument. This research employed a non-experimental pharmacoeconomic design with a prospective observational approach and applied a Cost Utility Analysis (CUA) method. The study was conducted at Berkah Pandeglang Hospital from February to April 2025. A total of 58 outpatient hypertensive patients who met the inclusion and exclusion criteria were enrolled. Data collected included direct medical costs and patients’ quality of life, which was assessed using the EQ-5D-5L questionnaire to calculate utility values and Quality-Adjusted Life Years (QALYs). The results showed that the total treatment cost for the amlodipine group was IDR 13,622,679, while the candesartan group incurred IDR 13,486,119, with no statistically significant difference in costs (p > 0.05). The QALY value in the amlodipine group was 0.189, while the candesartan group showed a slightly higher QALY of 0.195 during the 3-month observation period. The Average Cost Utility Ratio (ACUR) for amlodipine was IDR 72,078,725/QALY, whereas candesartan showed a lower ACUR of IDR 69,159,585/QALY. Incremental Cost Utility Ratio (ICUR) analysis indicated that candesartan provided slightly higher utility with lower costs compared to amlodipine. In conclusion, candesartan therapy demonstrated better cost efficiency than amlodipine in the management of outpatient hypertension during the study observation period.